(Q33893383)

29 July 2017

1 reference

title

Update on cyclophosphamide for systemic lupus erythematosus (English)

1 reference

systemic lupus erythematosus

29 July 2017

1 reference

Ortmann RA

1

1 reference

PubMed ID

10768217

29 July 2017

Klippel JH

series ordinal

2

1 reference

29 July 2017

1 May 2000

1 reference

Rheumatic Diseases Clinics of North America

29 July 2017

1 reference

29 July 2017

26

1 reference

29 July 2017

363-75, vii

1 reference

29 July 2017

2

1 reference

The course and treatment of lupus nephritis

29 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970143-5

7 January 2021

Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970143-5

7 January 2021

Effect of treatment on the evolution of renal abnormalities in lupus nephritis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970143-5

7 January 2021

Treatment of lupus nephritis: a meta-analysis of clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970143-5

7 January 2021

New York University/Hospital for Joint Diseases experience with intravenous cyclophosphamide treatment: efficacy in steroid unresponsive lupus nephritis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970143-5

7 January 2021

Intermittent cyclophosphamide for the treatment of autoimmune thrombocytopenia in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970143-5

7 January 2021

Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970143-5

7 January 2021

Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970143-5

7 January 2021

Systemic lupus erythematosus: emerging concepts. Part 1: Renal, neuropsychiatric, cardiovascular, pulmonary, and hematologic disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970143-5

7 January 2021

Prevention of gonadal damage during cytotoxic therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970143-5

7 January 2021

Immunoablative high-dose cyclophosphamide without stem-cell rescue for refractory, severe autoimmune disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970143-5

7 January 2021

Transverse myelopathy in SLE: clinical features and functional outcomes

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970143-5

7 January 2021

Sequential therapy for diffuse proliferative and membranous lupus nephritis: cyclophosphamide and prednisolone followed by azathioprine and prednisolone

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970143-5

7 January 2021

Cumulative rate of relapse of lupus nephritis after successful treatment with cyclophosphamide.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970143-5

7 January 2021

Cyclophosphamide therapy for lupus nephritis: poor renal survival in black Americans. Glomerular Disease Collaborative Network

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970143-5

7 January 2021

Treatment of lupus interstitial lung disease with intravenous cyclophosphamide

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970143-5

7 January 2021

Treatment-free remission in severe systemic lupus erythematosus following synchronization of plasmapheresis with subsequent pulse cyclophosphamide

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970143-5

7 January 2021

The favourable effect of cyclophosphamide pulse therapy in the treatment of massive pulmonary haemorrhage in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970143-5

7 January 2021

Fatal interstitial pneumonia due to cytomegalovirus following cyclophosphamide treatment in a patient with systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970143-5

7 January 2021

Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970143-5

7 January 2021

Successful treatment of gastrointestinal vasculitis due to systemic lupus erythematosus with intravenous pulse cyclophosphamide: a clinical case report and review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970143-5

7 January 2021

The effect of intravenous cyclophosphamide pulse on peripheral blood lymphocytes in lupus erythematosus patients

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970143-5

7 January 2021

Gastrointestinal vasculitis and pneumatosis intestinalis due to systemic lupus erythematosus: successful treatment with pulse intravenous cyclophosphamide

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970143-5

7 January 2021

Autologous marrow stem cell transplantation for severe systemic lupus erythematosus of long duration

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970143-5

7 January 2021

Side-effects of intravenous cyclophosphamide pulse therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970143-5

7 January 2021

Immunosuppressive treatment in severe connective tissue diseases: effects of low dose intravenous cyclophosphamide

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970143-5

7 January 2021

Mononeuritis multiplex in systemic lupus erythematosus: response to pulse intravenous cyclophosphamide.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970143-5

7 January 2021

Use of testosterone to prevent cyclophosphamide-induced azoospermia.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970143-5

7 January 2021

The economic impact of treatment of severe lupus nephritis with prednisone and intravenous cyclophosphamide.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970143-5

7 January 2021

Risk factors for ovarian failure in patients with systemic lupus erythematosus receiving cyclophosphamide therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970143-5

7 January 2021

Severe and prolonged jaundice in a lupus nephritis patient treated with cyclophosphamide

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970143-5

7 January 2021

Treatment of membranous lupus nephritis.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970143-5

7 January 2021

Role of intravenous cyclophosphamide in the treatment of severe neuropsychiatric systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970143-5

7 January 2021

Systemic lupus erythematosus associated with transverse myelitis and parkinsonian symptoms

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970143-5

7 January 2021

Neuropsychiatric systemic lupus erythematosus before and after immunosuppressive treatment: a FDG PET study.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970143-5

7 January 2021

Risk factors for serious infection during treatment with cyclophosphamide and high-dose corticosteroids for systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970143-5

7 January 2021

Effects of cyclophosphamide on the development of malignancy and on long-term survival of patients with rheumatoid arthritis. A 20-year followup study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970143-5

7 January 2021

Cytotoxic therapy in systemic lupus erythematosus. Experience from a single center

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970143-5

7 January 2021

Immunosuppressive drug use during pregnancy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970143-5

7 January 2021

Preserving renal function in patients with membranous nephropathy: daily oral chlorambucil compared with intermittent monthly pulses of cyclophosphamide

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970143-5

7 January 2021

Treatment of refractory, systemic lupus erythematosus-associated thrombocytopenia with intermittent low-dose intravenous cyclophosphamide

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970143-5

7 January 2021

Successful treatment of optic neuropathy in association with systemic lupus erythematosus using intravenous cyclophosphamide

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970143-5

7 January 2021

Intravenous pulse cyclophosphamide in the treatment of interstitial lung disease due to collagen vascular diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970143-5

7 January 2021

Synchronization of plasmapheresis and pulse cyclophosphamide in severe systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970143-5

7 January 2021

Preserving ovarian function in patients receiving cyclophosphamide

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970143-5

7 January 2021

Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970143-5

7 January 2021

Randomized controlled trial of pulse/synchronization cyclophosphamide/apheresis for proliferative lupus nephritis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970143-5

7 January 2021

Reversal of aplastic anaemia secondary to systemic lupus erythematosus by high-dose intravenous cyclophosphamide

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970143-5

7 January 2021

High-dose intravenous cyclophosphamide treatment of systemic lupus erythematosus-associated aplastic anemia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970143-5

7 January 2021

Nocardia choroidal abscess in a patient with systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970143-5

7 January 2021

Diffuse alveolar hemorrhage and systemic lupus erythematosus. Clinical presentation, histology, survival, and outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970143-5

7 January 2021

10.1016/S0889-857X(05)70143-5

Identifiers

DOI

1 reference

29 July 2017

1 reference

PubMed ID

10768217